カリフォルニア州における乳がんの臨床試験
カリフォルニア州内の拠点で、乳がんに関する179件の研究が参加者を募集しています。
カリフォルニア州内の都市
- Los Angeles72件の研究
- Baldwin Park45件の研究
- San Francisco43件の研究
- San Diego41件の研究
- Santa Monica27件の研究
- Mountain View25件の研究
- Irvine23件の研究
- Sacramento20件の研究
- Newport Beach16件の研究
- Orange14件の研究
- Santa Rosa11件の研究
- Vallejo10件の研究
- Fullerton9件の研究
- Burbank9件の研究
- Long Beach9件の研究
- Concord9件の研究
- Torrance9件の研究
- Westminster7件の研究
- Richmond7件の研究
- Oakland7件の研究
- Santa Clara7件の研究
- Roseville7件の研究
- Stockton7件の研究
- Santa Barbara6件の研究
- Indio6件の研究
- Fresno6件の研究
- San Jose6件の研究
- Pleasanton6件の研究
- Redwood City6件の研究
- Fremont6件の研究
- Huntington Beach6件の研究
- Santa Maria5件の研究
- Modesto5件の研究
- Anaheim5件の研究
- Whittier4件の研究
- Glendale4件の研究
- San Leandro4件の研究
- Vacaville4件の研究
- Antioch4件の研究
- Daly City4件の研究
- Elk Grove4件の研究
- Arden-Arcade4件の研究
- Riverside4件の研究
- San Bernardino4件の研究
- Alhambra4件の研究
- San Marcos4件の研究
- Pasadena4件の研究
- Bakersfield4件の研究
- Norwalk3件の研究
- Bellflower3件の研究
- Sunnyvale3件の研究
- Ontario3件の研究
- Santa Clarita3件の研究
- Berkeley3件の研究
- Upland3件の研究
- San Mateo3件の研究
- Salinas3件の研究
公式研究テキスト（英語）
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of San Diego Moores Cancer Center, La Jolla
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- Kaiser Permanente Fresno Orchard Plaza, Fresno
- 他10件
被験者募集中
18歳以上 · 全性別 · 2026/10/02更新 · NCT07059884Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Onco Inst of Hope and Innovation, Cerritos
- City of Hope National Medical, Duarte
- Providence Medical Foundation, Fullerton
- 他7件
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/10/02更新 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
- PCR Oncology, Arroyo Grande
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
- 他20件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- City of Hope - Duarte Cancer Center, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- City of Hope, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles
- Stanford Medicine Cancer Center, Stanford
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07701941A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Oncology Institute, Long Beach
- Cancer & Blood Research Center, Los Alamitos
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07102381Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- City of Hope Comprehensive Cancer Center, Duarte
- University of California Los Angeles, Los Angeles
- University of California San Diego Moores Cancer Center, San Diego
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06625775A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Beverly Hills Cancer Center, Beverly Hills
- MemorialCare Orange Coast Medical Center, Fountain Valley
- City of Hope at Orange County Lennar Foundation Cancer Center, Irvine
- 他3件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06369285Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- City of Hope at Long Beach Elm, Long Beach
- 他1件
被験者募集中第2相
70歳以上 · 全性別 · 2026/10/01更新 · NCT04305834Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Oncology Institute of Hope and Innovation, Cerritos
- Ellison Medical Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
- 他3件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06324357Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- California Protons Cancer Therapy Center, San Diego
被験者募集中第3相
19歳以上 · 女性 · 2026/09/29更新 · NCT05856773A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Newport Beach
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05877599Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- California Protons Cancer Therapy Center, San Diego
被験者募集中第2相
50歳以上 · 女性 · 2026/09/29更新 · NCT01766297IKS014 in Advanced Solid Tumors That Express HER2
- Hoag Memorial Hospital Presbyterian, Newport Beach
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05872295A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Los Angeles Hematology Oncology Medical Group ( Site 0026), Los Angeles
- Hoag Memorial Hospital Presbyterian ( Site 0025), Newport Beach
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07060807A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
- Los Angeles Cancer Network, Los Angeles
- Community Clinical Trials, Orange
被験者募集中第2相
18歳以上 · 女性 · 2026/09/25更新 · NCT07054190A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Roy and Patricia Disney Family Cancer Center ( Site 0055), Burbank
- Community Cancer Institute ( Site 0100), Clovis
- Providence Medical Foundation ( Site 0080), Fullerton
- 他4件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Providence Medical Foundation-Oncology ( Site 0020), Fullerton
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06312176The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Providence Medical Foundation, Eureka
- Providence Medical Foundation, Santa Rosa
被験者募集中第3相
60歳以上 · 全性別 · 2026/09/25更新 · NCT06377852A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Fountain Valley
- Research Site, Glendale
- Research Site, Sacramento
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- City of Hope, Duarte
- UC San Diego Moores Cancer Center, La Jolla
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07007559A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, Santa Monica
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT07229313A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
- Precision NextGen Oncology and Research Center (Investigational Site number USA-001), Beverly Hills
被験者募集中第1相
18歳〜80歳 · 女性 · 2026/09/23更新 · NCT07401381Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Beverly Hills
- Clinical Trial Site, La Jolla
- Clinical Trial Site, Los Alamitos
- 他8件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Marin Cancer Care, Greenbrae
- Loma Linda University, Loma Linda
- Cancer and Blood Research Center, Los Alamitos
- 他3件
被験者募集中
18歳以上 · 全性別 · 2026/09/23更新 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Community Cancer Institute, Clovis
- City of Hope, Duarte
- Epic Care - Emeryville, Emeryville
- 他19件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- City of Hope, Duarte
- University of California, Los Angeles (UCLA), Santa Monica
- Stanford University Medical Center, Stanford
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07114601A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- City of Hope, Duarte
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- USC/Norris Comprehensive Cancer Center, Los Angeles
- 他1件
被験者募集中第2相
18歳以上 · 女性 · 2026/09/22更新 · NCT07287098A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Hoag Memorial Hospital Presbyterian, Newport Beach
- Stanford University Medical Center, Stanford
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213791A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Disney Family Cancer Center, Burbank
- City of Hope, Corona
- City of Hope Comprehensive Cancer Center, Duarte
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05894239Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of California Irvine, Irvine
- University of California Los Angeles, Los Angeles
- University of California Davis, Sacramento
- 他2件
被験者募集中健康なボランティア歓迎
30歳〜74歳 · 女性 · 2026/09/21更新 · NCT02620852Pulsed Electric Field Ablation for Metastatic Breast Cancer
- University of California San Francisco, San Francisco
被験者募集中
18歳以上 · 全性別 · 2026/09/18更新 · NCT07487844ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- University Of California - San Diego Moores Cancer Center, La Jolla
- Cancer and Blood Specialty Clinic (CBSC), Los Alamitos
- Cedar Sinai - Samuel Oschin Cancer Center, Los Angeles
- 他4件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Duarte
- City of Hope, Irvine, Irvine
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Beverly Hills Cancer Center, Beverly Hills
- Hoag Memorial Hospital Presbyterian, Newport Beach
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT06827236ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health
- UC Davis, Sacramento
被験者募集中観察研究
18歳〜94歳 · 女性 · 2026/09/17更新 · NCT07505797A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
- University of California, Los Angeles (Specimen Analysis only), Los Angeles
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 全性別 · 2026/09/16更新 · NCT06780176A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- UCSF Cancer Center Berkeley, Berkeley
- Cedars-Sinai Cancer Beverly Hills, Beverly Hills
- City of Hope National Medical Center, Duarte
- 他19件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06492616ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。